Trials / Active Not Recruiting
Active Not RecruitingNCT07148557
A Study of Single Dose of LP-003 in Adolescent Subjects
A Single-center, Open-label, Phase Ib Clinical Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of LP-003 Injection in Adolescent Subjects Aged 12-18 Years
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Longbio Pharma · Industry
- Sex
- All
- Age
- 12 Years – 18 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center, open-label, phase Ib clinical study to evaluate the safety, pharmacokinetics and pharmacodynamic characteristics of LP-003 injection in adolescent subjects aged 12-18 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LP-003 Dose 1 (Single) | A single dose of LP-003 (400 mg/dose) was SC |
| BIOLOGICAL | LP-003 Dose 2 (Single) | A single dose of LP-003 (600 mg/dose) was SC |
Timeline
- Start date
- 2025-10-01
- Primary completion
- 2026-05-31
- Completion
- 2026-09-30
- First posted
- 2025-08-29
- Last updated
- 2026-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07148557. Inclusion in this directory is not an endorsement.